Liaoning Tianlong Pharmaceutical Co., Ltd.

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

This product is a vasodilator that can improve blood rheology and reduce peripheral vascular resistance. This product can promote glucose to pass through the blood-brain barrier, enhance the utilization of glucose and oxygen in brain cells, and improve brain sugar metabolism and brain function.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the binding of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.